1. Influenza A and B
1.1. Oseltamivir (PO)
1.1.1. Inhibition of release from cell
1.1.2. Fatal neuropsychiatric
1.1.3. Serious skin rxn
1.1.4. Hepatic metabolism
1.1.5. Renal elimination
1.2. Zanamivir (Inhalation)
1.2.1. Inhibition of release from cell
1.2.2. Fatal bronchospasm with underlying pulmonary disease
1.2.3. Renal elimination
2. Influenza A
2.1. Amantadine (PO)
2.1.1. Inhibition of viral entry or uncoating
2.1.2. Contraindicated with narrow angle glaucoma
2.1.3. Contraindicated with breastfeeding
2.1.4. Neurotoxicity
2.1.5. Orthostatic hypotension
2.1.6. Renal elimination
2.2. Rimantadine (PO)
2.2.1. Inhibition of viral entry or uncoating
2.2.2. Hepatic metabolism
2.2.3. Renal elimination
3. RSV
3.1. Ribavirin (Inhalation, IV)
3.1.1. Inhibition of viral nucleic acid synthesis
3.1.2. Hemolytic anemia (BBW)
3.1.3. Male/female teratogen (BBW)
4. Adenovirus
4.1. Cidofivir (IV)
4.1.1. Inhibition of viral DNA polymerase
4.1.2. Nephrotoxic
4.1.3. Metabolic activation
4.1.4. Renal elimination
5. Rhinovirus
5.1. No treatment
6. Prevention
6.1. Influenza A and B
6.1.1. Inactivated, live vaccines
6.1.2. Oseltamivir
6.1.3. Zanamivir
6.2. RSV
6.2.1. Palivizumab (IM)
6.2.1.1. Not for children, safety issues
6.3. Adenovirus
6.3.1. Vaccine for types 4 and 7
6.4. Rhinovirus
6.4.1. Alfa interferon (Intranasal)
6.4.2. Ribavirin
6.5. Varicella-zoster
6.5.1. Vaccine
7. Human metapneumovirus
7.1. Ribivarin (IV)
8. Hantavirus
8.1. Ribavirin (IV)
9. Varicella-zoster
9.1. Acyclovir (IV)
9.1.1. Inhibition of viral DNA polymerase
9.1.2. Nephrotoxic
9.1.3. Neurotoxicity - seizures
9.1.4. Thrombocytopenia
9.1.5. Renal elimination
9.2. Valacyclovir (PO)
9.2.1. Thrombocytopenia